AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30666100 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 28154349 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 g/d of ALA‐DAG
Number of subjects: 16
Study 28154349 — intervention group
Group type: COMPARATOR
Intervention: TAG (control)
Number of subjects: 16
Study 25932833 — intervention group
Group type: EXPERIMENTAL
Intervention: Mnemonic counseling
Number of subjects: 90
Study 25932833 — intervention group
Group type: COMPARATOR
Intervention: Standard counseling
Number of subjects: 90
Study 24035165 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 1150
Study 24035165 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 1150
Study 21814588 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin (single dose, 200 µg/kg)
Number of subjects: 198
Study 21814588 — intervention group
Group type: COMPARATOR
Intervention: Thiabendazole (two daily doses of 25 mg/kg for two days)
Number of subjects: 198
Study 19405831 — intervention group
Group type: EXPERIMENTAL
Intervention: Acellular dermal matrix (ADM)
Number of subjects: 20
Study 19405831 — intervention group
Group type: COMPARATOR
Intervention: Polytetrafluoroethylene (PTFE) membrane
Number of subjects: 20
Study 16896932 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined diet and exercise programme (47 intervention)
Number of subjects: 97
Study 16896932 — intervention group
Group type: COMPARATOR
Intervention: Control group (50 control subjects)
Number of subjects: 97
Study 16896932 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle programme
Number of subjects: 97
Study 15303645 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled plus oral corticosteroids (O group)
Number of subjects: 101
Study 15303645 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid treatment in unstable asthmatics
Number of subjects: 101
Study 15303645 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid treatment intensity
Number of subjects: 101
Study 15303645 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid treatment
Number of subjects: 101
Study 10641044 — intervention group
Group type: EXPERIMENTAL
Intervention: Taiga Wurzel (25 drops three times daily for 30 days)
Number of subjects: 50
Study 10641044 — intervention group
Group type: COMPARATOR
Intervention: Echinacea (40 drops three times daily for 30 days)
Number of subjects: 50
Study 8694312 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.6 mg/kg
Number of subjects: 60
Study 8694312 — intervention group
Group type: COMPARATOR
Intervention: Vecuronium 0.1 mg/kg
Number of subjects: 60
Study 8694312 — intervention group
Group type: COMPARATOR
Intervention: Atracurium 0.5 mg/kg
Number of subjects: 60
Study 1426372 — intervention group
Group type: EXPERIMENTAL
Intervention: Gonadotropin-releasing hormone agonists (GnRH-a)
Number of subjects: 1636
Study 1426372 — intervention group
Group type: COMPARATOR
Intervention: Short flare-up GnRH-a protocols
Number of subjects: 1636
Study 4082084 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening primrose oil (EPO) 12 capsules/day for 8 weeks
Number of subjects: 21
Study 4082084 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 2 weeks followed by placebo for 8 weeks
Number of subjects: 21
Study 4082084 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening primrose oil (EPO)
Number of subjects: 21
Study 4082084 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 31615581 — intervention group
Group type: EXPERIMENTAL
Intervention: RecoveryMANTRA (experimental group)
Number of subjects: 187
Study 31615581 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU) (control group)
Number of subjects: 187
Study 29846607 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily modified-release hydrocortisone
Number of subjects: 89
Study 29846607 — intervention group
Group type: COMPARATOR
Intervention: Multiple daily glucocorticoid doses
Number of subjects: 89
Study 28199748 — intervention group
Group type: EXPERIMENTAL
Intervention: DL‐PDT with topical 10% methylene blue gel
Number of subjects: 40
Study 28199748 — intervention group
Group type: COMPARATOR
Intervention: DL‐PDT with hematoxylin (placebo)
Number of subjects: 40
Study 26348226 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise in nature (outdoor)
Number of subjects: 19
Study 26348226 — intervention group
Group type: COMPARATOR
Intervention: Indoor exercise
Number of subjects: 19
Study 24002279 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-4-6 schedule
Number of subjects: 400
Study 24002279 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-5 schedule
Number of subjects: 400
Study 24002279 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 different PCV13 immunization schedules
Number of subjects: 400
Study 21560266 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (1 mg, pressurized metered dose inhaler)
Number of subjects: 12
Study 21560266 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 19055209 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (up to 15 sessions over 3 months)
Number of subjects: 487
Study 19055209 — intervention group
Group type: COMPARATOR
Intervention: Control (routine care alone)
Number of subjects: 487
Study 19055209 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 487
Study 19055209 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 487
Study 17015555 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized parent voice smoke alarm
Number of subjects: 24
Study 17015555 — intervention group
Group type: COMPARATOR
Intervention: Conventional residential tone smoke alarm
Number of subjects: 24
Study 12663573 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-care management system (n = 84)
Number of subjects: 169
Study 12663573 — intervention group
Group type: COMPARATOR
Intervention: Usual medical care (n = 85)
Number of subjects: 169
Study 10704275 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote organ ischaemia via tourniquet (3 min ischaemia, 2 min reperfusion)
Number of subjects: 8
Study 10704275 — intervention group
Group type: COMPARATOR
Intervention: Control group (no preconditioning)
Number of subjects: 8
Study 8865530 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin (200 IU anti-factor Xa/kg, subcutaneously once daily)
Number of subjects: 253
Study 8865530 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH, continuous intravenous infusion)
Number of subjects: 253
Study 8865530 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin
Number of subjects: 253
Study 8865530 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH)
Number of subjects: 253
Study 8865530 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin and UFH
Number of subjects: 253
Study 1298487 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine HCl with 1:200,000 epinephrine
Number of subjects: 24
Study 1298487 — intervention group
Group type: COMPARATOR
Intervention: 2% lidocaine HCl with 1:100,000 epinephrine
Number of subjects: 24
Study 1298487 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative discomfort
Number of subjects: 24
Study 1298487 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall success rate
Number of subjects: 24
Study 6377843 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety Reduction
Number of subjects: 53
Study 6377843 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 53
Study 2423343 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 2423343 — intervention group
Group type: COMPARATOR
Intervention: Verapamil 3 X 80 mg
Number of subjects: 10
Study 29299613 — intervention group
Group type: EXPERIMENTAL
Intervention: Critical Time Intervention (CTI)
Number of subjects: 136
Study 29299613 — intervention group
Group type: COMPARATOR
Intervention: Care-as-usual
Number of subjects: 136
Study 26451007 — intervention group
Group type: EXPERIMENTAL
Intervention: Core stability exercises for 15 min/day in addition to conventional therapy
Number of subjects: 80
Study 26451007 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 80
Study 25896352 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide treatment for 10 weeks
Number of subjects: 24
Study 25896352 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 24
Study 23720785 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stretching and deep breathing exercise (MBX)
Number of subjects: 29
Study 23720785 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 29
Study 19797974 — intervention group
Group type: COMPARATOR
Intervention: Coronary Artery Bypass Grafting (CABG)
Number of subjects: 472
Study 19797974 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous Coronary Intervention (PCI)
Number of subjects: 472
Study 19055813 — intervention group
Group type: EXPERIMENTAL
Intervention: FACT (Flexible Assertive Community Treatment)
Number of subjects: 0
Study 19055813 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (control)
Number of subjects: 0
Study 16634535 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 fatty acids
Number of subjects: 161
Study 16634535 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 161
Study 12789171 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab 5 mg/kg
Number of subjects: 33
Study 12789171 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab 10 mg/kg
Number of subjects: 33
Study 12789171 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 11199369 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant IFN-alpha2a
Number of subjects: 95
Study 11199369 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-alpha2b
Number of subjects: 95
Study 11199369 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphoblastoid IFN-alpha1
Number of subjects: 95
Study 11199369 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall (all treatments)
Number of subjects: 95
Study 8617708 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (200 mg/day for 10 days)
Number of subjects: 30
Study 8617708 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 8617708 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 30
Study 1614045 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilevalol 200 mg
Number of subjects: 8
Study 1614045 — intervention group
Group type: COMPARATOR
Intervention: Enalapril 5 mg
Number of subjects: 8
Study 6584445 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% metronidazole solution in dialysis tubing
Number of subjects: 10
Study 6584445 — intervention group
Group type: COMPARATOR
Intervention: 0.2% chlorhexidine subgingival irrigation
Number of subjects: 10
Study 31757218 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy (CEA)
Number of subjects: 0
Study 31757218 — intervention group
Group type: COMPARATOR
Intervention: Medical management
Number of subjects: 0
Study 27821548 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive Action (PA) program
Number of subjects: 0
Study 27821548 — intervention group
Group type: COMPARATOR
Intervention: Control condition activities
Number of subjects: 0
Study 25650040 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyanoacrylate embolization (CAE) with the VenaSeal Sapheon Closure System (n = 108)
Number of subjects: 222
Study 25650040 — intervention group
Group type: COMPARATOR
Intervention: Radiofrequency ablation (RFA) with the ClosureFast system (n = 114)
Number of subjects: 222
Study 25650040 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyanoacrylate embolization (CAE)
Number of subjects: 222
Study 25650040 — intervention group
Group type: COMPARATOR
Intervention: Radiofrequency ablation (RFA)
Number of subjects: 222
Study 23643716 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking program (8-week physiotherapy-delivered walking program)
Number of subjects: 60
Study 23643716 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise class (8-week group supervised exercise class, 1 class/week)
Number of subjects: 60
Study 23643716 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual physiotherapy (1-to-1 advice, manual therapy, and exercise)
Number of subjects: 60
Study 20336348 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilengitide 500 mg IV twice weekly
Number of subjects: 44
Study 20336348 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilengitide 2000 mg IV twice weekly
Number of subjects: 44
Study 20336348 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 44
Study 19246849 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan 40 mg and HCTZ 12.5 mg once daily
Number of subjects: 21
Study 19246849 — intervention group
Group type: COMPARATOR
Intervention: Losartan 50 mg and HCTZ 12.5 mg once daily
Number of subjects: 21
Study 16725141 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulosa cell‐conditioned medium from smokers
Number of subjects: 100
Study 16725141 — intervention group
Group type: COMPARATOR
Intervention: Granulosa cell‐conditioned medium from nonsmokers
Number of subjects: 100
Study 16725141 — intervention group
Group type: EXPERIMENTAL
Intervention: Follicular fluid from smokers
Number of subjects: 100
Study 16725141 — intervention group
Group type: COMPARATOR
Intervention: Follicular fluid from nonsmokers
Number of subjects: 100
Study 16725141 — intervention group
Group type: EXPERIMENTAL
Intervention: HUVECs cultured with follicular fluid from smokers
Number of subjects: 100
Study 16725141 — intervention group
Group type: COMPARATOR
Intervention: HUVECs cultured with follicular fluid from nonsmokers
Number of subjects: 100
Study 16725141 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotinine concentration in smoking women
Number of subjects: 100
Study 16725141 — intervention group
Group type: COMPARATOR
Intervention: Cotinine concentration in nonsmoking women
Number of subjects: 100
Study 15019670 — intervention group
Group type: EXPERIMENTAL
Intervention: On-pump CABG with cardiopulmonary bypass and cardioplegic arrest
Number of subjects: 114
Study 15019670 — intervention group
Group type: COMPARATOR
Intervention: Off-pump CABG without cardiopulmonary bypass and cardioplegic arrest
Number of subjects: 114
Study 11246304 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasogastric sucralfate
Number of subjects: 20
Study 11246304 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ranitidine
Number of subjects: 20
Study 9497019 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg nicotine patch (Nicotrol)
Number of subjects: 106
Study 9497019 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg oral cotinine fumarate
Number of subjects: 106
Study 9497019 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of nicotine patch and cotinine
Number of subjects: 106
Study 9497019 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 106
Study 9497019 — intervention group
Group type: COMPARATOR
Intervention: Placebo drug
Number of subjects: 106
Study 7979282 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone 1 g administered immediately before PE (group I)
Number of subjects: 12
Study 7979282 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone 3 g administered immediately before PE (group I)
Number of subjects: 12
Study 7979282 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone 1 g administered 6 hours before PE (group II)
Number of subjects: 12
Study 7979282 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone 3 g administered 6 hours before PE (group II)
Number of subjects: 12
Study 2658529 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilevalol administered once daily
Number of subjects: 0
Study 2658529 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilevalol
Number of subjects: 0
Study 2658529 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 0
Study 1174085 — intervention group
Group type: EXPERIMENTAL
Intervention: Bumetanide 0.25 mg
Number of subjects: 0
Study 1174085 — intervention group
Group type: EXPERIMENTAL
Intervention: Bumetanide 0.5 mg
Number of subjects: 0
Study 1174085 — intervention group
Group type: EXPERIMENTAL
Intervention: Bumetanide (general)
Number of subjects: 0
Study 30506693 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab with immunomodulators
Number of subjects: 192
Study 30506693 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab monotherapy
Number of subjects: 192
Study 27615542 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition counseling intervention (monthly one-on-one sessions for 12 months)
Number of subjects: 22
Study 27615542 — intervention group
Group type: COMPARATOR
Intervention: Standard care and nutrition education materials (control group)
Number of subjects: 22
Study 24810891 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoluminal venous laser therapy (980 nm, continuous mode, 30 W)
Number of subjects: 449
Study 24810891 — intervention group
Group type: EXPERIMENTAL
Intervention: High ligation and invaginating stripping
Number of subjects: 449
Study 24810891 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of both (laser and high ligation)
Number of subjects: 449
Study 24810891 — intervention group
Group type: COMPARATOR
Intervention: Control/Stripping (C/S)
Number of subjects: 449
Study 23890679 — intervention group
Group type: EXPERIMENTAL
Intervention: Caseload midwifery
Number of subjects: 1532
Study 23890679 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 1532
Study 23890679 — intervention group
Group type: EXPERIMENTAL
Intervention: Early admission to hospital (before cervix was 5 cm dilated)
Number of subjects: 1532
Study 23890679 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmentation of labour
Number of subjects: 1532
Study 23890679 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of epidural analgesia
Number of subjects: 1532
Study 21568186 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete prevention program
Number of subjects: 263
Study 21568186 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial program
Number of subjects: 263
Study 21568186 — intervention group
Group type: COMPARATOR
Intervention: Non-treatment control
Number of subjects: 263
Study 21568186 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants who completed inter-session interactive activities
Number of subjects: 263
Study 19450644 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-1 DNA prime-MVA boost vaccine
Number of subjects: 0
Study 16676650 — intervention group
Group type: COMPARATOR
Intervention: Passive rewarming (PASS)
Number of subjects: 16
Study 16676650 — intervention group
Group type: COMPARATOR
Intervention: Cranial-neck rewarming (CN)
Number of subjects: 16
Study 16676650 — intervention group
Group type: COMPARATOR
Intervention: Cranial-neck and inhalation rewarming (CNIR)
Number of subjects: 16
Study 15537171 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigational anti-malarial phytomedicine (AM1) 250mg capsule with 1000mg paracetamol (PCM) tablets
Number of subjects: 0
Study 15537171 — intervention group
Group type: COMPARATOR
Intervention: 1000mg paracetamol (PCM) tablets alone (control)
Number of subjects: 0
Study 11501511 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol 3 microg g(‐1) ointment (Silkis ointment)
Number of subjects: 0
Study 9217191 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG-rHuMGDF at 0.03, 0.1, 0.3, or 1.0 microg/kg/d for 10 days
Number of subjects: 0
Study 9217191 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG-rHuMGDF at 0.1 microg/kg/d
Number of subjects: 0
Study 9217191 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8483855 — intervention group
Group type: EXPERIMENTAL
Intervention: Single session of family-oriented nutritional education
Number of subjects: 295
Study 8483855 — intervention group
Group type: EXPERIMENTAL
Intervention: Four multiple 90-min sessions of family-oriented nutritional education
Number of subjects: 295
Study 3038418 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (50 mg bid)
Number of subjects: 9
Study 3038418 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 3038418 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 9
Study 3038418 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 9
Study 29635502 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding-promotion intervention
Number of subjects: 0
Study 29635502 — intervention group
Group type: COMPARATOR
Intervention: Control (no breastfeeding-promotion intervention)
Number of subjects: 0
Study 29635502 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding ≥12 months
Number of subjects: 0
Study 29635502 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding <12 months
Number of subjects: 0
Study 29635502 — intervention group
Group type: EXPERIMENTAL
Intervention: Instrumental variable analysis for breastfeeding duration
Number of subjects: 0
Study 26742700 — intervention group
Group type: EXPERIMENTAL
Intervention: Benidipine
Number of subjects: 88
Study 26742700 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 88
Study 24685559 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy and motivational enhancement therapy with additional check-ups
Number of subjects: 74
Study 24685559 — intervention group
Group type: COMPARATOR
Intervention: Cognitive behavioral therapy and motivational enhancement therapy without additional check-ups
Number of subjects: 74
Study 23797469 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.625 mg CEE with or without 2.5 mg medroxyprogesterone acetate
Number of subjects: 1326
Study 23797469 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1326
Study 20588105 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose ritonavir (100 mg daily)
Number of subjects: 20
Study 20588105 — intervention group
Group type: COMPARATOR
Intervention: Raltegravir (400 mg twice daily)
Number of subjects: 20
Study 18763235 — intervention group
Group type: COMPARATOR
Intervention: Prolonged-release melatonin (PR-M) 2 mg
Number of subjects: 16
Study 18763235 — intervention group
Group type: COMPARATOR
Intervention: Zolpidem 10 mg
Number of subjects: 16
Study 18763235 — intervention group
Group type: COMPARATOR
Intervention: Combination of PR-M 2 mg and Zolpidem 10 mg
Number of subjects: 16